Improving HER2 Biomarker Testing in mCRC

Ryan Haumschild, PharmD, MS, MBA, reviews risk factors for colorectal cancer, including social determinants and at-risk demographics.

Dr Kristen Ciombor explores clinical impacts during the treatment of patients with metastatic or nonmetastatic colorectal cancer.

Dr Kristen Ciombor discusses utilization of biomarkers and molecular testing in the treatment of patients with CRC.

Dr Haumschild aligns payer considerations with molecular testing and biomarker application for treatment of patients with mCRC.

In his final thoughts, Dr Haumschild outlines opportunities for next-generation sequencing in treatment for metastatic colorectal cancer.

Dr Ciombor provides her insight on determining appropriate testing strategies for patients with metastatic colorectal cancer.

Testing prioritization and frequency are highlighted in Dr Ciombor’s final insights for this HER2 biomarker focus.

Kanwal Raghav, MD, MBBS, discusses appropriate candidates for HER2 testing and current utilization strategies for biomarker testing in mCRC.

Kanwal Raghav, MD, MBB, examines unmet needs in next-generation sequencing and barriers to coverage in this metastatic colorectal cancer discussion.

Kanwal Raghav, MD, MBBS, references several HER2 clinical trials, each presenting unique drug combinations to address metastatic colorectal cancer.

HER2+ targeted therapy outcomes are evaluated, particularly when combined with prior or subsequent chemotherapy.

Kanwal Raghav, MD, MBBS, provides his closing insights, with a focus on HER2-targeted therapy uptake in metastatic colorectal cancer.